Studies (12 shown)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
A Study of Olomorasib (LY3537982) in Healthy Participants
A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
A Study of [14C]-LY3537982 in Healthy Participants
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants